StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Provectus Biopharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $336.11K, down 45.5% year over year. For fiscal 2025 it was $336.11K, down 45.5% from the year before. The highest annual figure on record is $989.04K in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$336.11K-45.5%
FY2024Dec 31, 2024$617.14K+10.7%
FY2023Dec 31, 2023$557.71K-43.6%
FY2022Dec 31, 2022$989.04K–
FY2015Dec 31, 2015$0–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–
FY2012Dec 31, 2012$0–
FY2011Dec 31, 2011$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$57.48K-77.5%
Q1 FY2025Mar 31, 2025$278.63K+17.0%
Q4 FY2024Dec 31, 2024$14.33K-88.2%
Q3 FY2024Sep 30, 2024$109.75K+57.4%
Q2 FY2024Jun 30, 2024$254.99K+57.6%
Q1 FY2024Mar 31, 2024$238.07K+16.1%
Q4 FY2023Dec 31, 2023$121.11K-26.5%
Q3 FY2023Sep 30, 2023$69.73K-77.9%
Q2 FY2023Jun 30, 2023$161.84K-49.7%
Q1 FY2023Mar 31, 2023$205.03K+9.3%
Q4 FY2022Dec 31, 2022$164.84K–
Q3 FY2022Sep 30, 2022$314.89K–
Q2 FY2022Jun 30, 2022$321.71K–
Q1 FY2022Mar 31, 2022$187.61K–
Q3 FY2016Sep 30, 2016$0–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?